文献速递糖尿病肥胖与代谢综合征

每周一次司美格鲁肽对比每日一次西格列汀作为二甲双胍、噻唑烷二酮或两者联合治疗附加方案在2型糖尿病患者中的疗效与安全性(SUSTAIN 2):一项56周、双盲、3a期随机试验

Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial.
PubMed 文献 · Lancet Diabetes Endocrinol · 2017-04-03

SUSTAIN 2试验纳入二甲双胍和/或噻唑烷二酮治疗血糖控制不佳的2型糖尿病患者1231例,随机接受每周一次司美格鲁肽0.5 mg、1.0 mg或每日一次西格列汀100 mg治疗56周。结果显示司美格鲁肽在降低HbA1c和体重方面优于西格列汀,安全性与其它GLP-1受体激动剂相似,作者认为司美格鲁肽可能是该类患者的有效附加治疗选择。

要点

  • 司美格鲁肽0.5 mg和1.0 mg组HbA1c较基线分别降低1.3%和1.6%,西格列汀组降低0.5%。
  • 司美格鲁肽0.5 mg和1.0 mg组体重较基线分别降低4.3 kg和6.1 kg,西格列汀组降低1.9 kg。
  • 因不良事件停药比例:司美格鲁肽0.5 mg组8%、1.0 mg组10%、西格列汀组3%;最常见不良事件为胃肠道反应。

核心结论

  • 每周一次司美格鲁肽在改善血糖控制和降低体重方面优于西格列汀,安全性与其它GLP-1受体激动剂相似。
  • 作者认为司美格鲁肽似乎是该类患者人群的有效附加治疗选择。

研究设计与样本

  • 56周、3a期、随机、双盲、双模拟、活性对照、平行组、多国、多中心试验(SUSTAIN 2),在18个国家的128个中心进行。
  • 纳入年龄≥18岁(日本≥20岁)、诊断为2型糖尿病、尽管稳定使用二甲双胍和/或噻唑烷二酮但血糖控制不佳(HbA1c 7.0-10.5% [53.0-91.0 mmol/mol])的患者。
  • 随机分配(2:2:1:1)至皮下司美格鲁肽0.5 mg每周一次+口服西格列汀安慰剂每日一次、皮下司美格鲁肽1.0 mg每周一次+口服西格列汀安慰剂每日一次、口服西格列汀100 mg每日一次+皮下司美格鲁肽安慰剂0.5 mg每周一次、或口服西格列汀100 mg每日一次+皮下司美格鲁肽安慰剂1.0 mg每周一次;两个西格列汀100 mg组合并分析。
  • 改良意向治疗人群(所有随机分配且至少接受一剂研究药物的参与者)共1225例:司美格鲁肽0.5 mg组409例、司美格鲁肽1.0 mg组409例、西格列汀100 mg组407例。

主要发现

  • 基线平均HbA1c为8.1%(SD 0.93);第56周时,司美格鲁肽0.5 mg组HbA1c降低1.3%,司美格鲁肽1.0 mg组降低1.6%,西格列汀组降低0.5%(估计治疗差异 vs 西格列汀:司美格鲁肽0.5 mg为-0.77% [95% CI -0.92 to -0.62],司美格鲁肽1.0 mg为-1.06% [-1.21 to -0.91];两个司美格鲁肽剂量对比西格列汀的非劣效性和优效性p<0.0001)。
  • 基线平均体重为89.5 kg(SD 20.3);第56周时,司美格鲁肽0.5 mg组体重降低4.3 kg,司美格鲁肽1.0 mg组降低6.1 kg,西格列汀组降低1.9 kg(估计治疗差异 vs 西格列汀:司美格鲁肽0.5 mg为-2.35 kg [95% CI -3.06 to -1.63],司美格鲁肽1.0 mg为-4.20 kg [-4.91 to -3.49];两个司美格鲁肽剂量对比西格列汀的优效性p<0.0001)。
  • 因不良事件停药的患者比例:司美格鲁肽0.5 mg组33例(8%),司美格鲁肽1.0 mg组39例(10%),西格列汀组12例(3%)。
  • 两个司美格鲁肽组最常见的不良事件为胃肠道反应:恶心在司美格鲁肽0.5 mg组73例(18%)、司美格鲁肽1.0 mg组72例(18%)、安慰剂组30例(7%)中报告;腹泻在司美格鲁肽0.5 mg组54例(13%)、司美格鲁肽1.0 mg组53例(13%)、安慰剂组29例(7%)中报告。
  • 血糖证实的低血糖:司美格鲁肽0.5 mg组7例(2%),司美格鲁肽1.0 mg组2例(<1%),西格列汀组5例(1%);共有6例致死性事件(司美格鲁肽0.5 mg组2例、司美格鲁肽1.0 mg组1例、西格列汀组3例),均未认为可能与试验药物相关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Semaglutide is a novel glucagon-like peptide-1 (GLP-1) analogue, suitable for once-weekly subcutaneous administration, in development for treatment of type 2 diabetes. We assessed the efficacy and safety of semaglutide versus the dipeptidyl peptidase-4 (DPP-4) inhibitor sitagliptin in patients with type 2 diabetes inadequately controlled on metformin, thiazolidinediones, or both. METHODS: We did a 56-week, phase 3a, randomised, double-blind, double-dummy, active-controlled, parallel-group, multinational, multicentre trial (SUSTAIN 2) at 128 sites in 18 countries. Eligible patients were aged at least 18 years (or at least 20 years in Japan) and diagnosed with type 2 diabetes, with insufficient glycaemic control (HbA1c 7·0-10·5% [53·0-91·0 mmol/mol]) despite stable treatment with metformin, thiazolidinediones, or both. We randomly assigned participants (2:2:1:1) using an interactive voice or web response system to 56 weeks of treatment with subcutaneous semaglutide 0·5 mg once weekly plus oral sitagliptin placebo once daily, subcutaneous semaglutide 1·0 mg once weekly plus oral sitagliptin placebo once daily, oral sitagliptin 100 mg once daily plus subcutaneous semaglutide placebo 0·5 mg once weekly, or oral sitagliptin 100 mg once daily plus subcutaneous semaglutide placebo 1·0 mg once weekly. The two oral sitagliptin 100 mg groups (with semaglutide placebo 0·5 mg and 1·0 mg) were pooled for the analyses. The primary endpoint was change in HbA1c from baseline to week 56, assessed in the modified intention-to-treat population (all randomly assigned participants who received at least one dose of study drug); change in bodyweight from baseline to week 56 was the confirmatory secondary endpoint. Safety endpoints included adverse events and hypoglycaemic episodes. This trial is registered with ClinicalTrials.gov, number NCT01930188. FINDINGS: Between Dec 2, 2013, and Aug 5, 2015, we randomly assigned 1231 participants; of the 1225 included in the modified intention-to-treat analysis, 409 received semaglutide 0·5 mg, 409 received semaglutide 1·0 mg, and 407 received sitagliptin 100 mg. Mean baseline HbA1c was 8·1% (SD 0·93); at week 56, HbA1c was reduced by 1·3% in the semaglutide 0·5 mg group, 1·6% in the semaglutide 1·0 mg group, and 0·5% with sitagliptin (estimated treatment difference vs sitagliptin -0·77% [95% CI -0·92 to -0·62] with semaglutide 0·5 mg and -1·06% [-1·21 to -0·91] with semaglutide 1·0 mg; p<0·0001 for non-inferiority and for superiority, for both semaglutide doses vs sitagliptin). Mean baseline bodyweight was 89·5 kg (SD 20·3); at week 56, bodyweight reduced by 4·3 kg with semaglutide 0·5 mg, 6·1 kg with semaglutide 1·0 mg, and 1·9 kg with sitagliptin (estimated treatment difference vs sitagliptin -2·35 kg [95% CI -3·06 to -1·63] with semaglutide 0·5 mg and -4·20 kg [-4·91 to -3·49] with semaglutide 1·0 mg; p<0·0001 for superiority, for both semaglutide doses vs sitagliptin). The proportion of patients who discontinued treatment because of adverse events was 33 (8%) for semaglutide 0·5 mg, 39 (10%) for semaglutide 1·0 mg, and 12 (3%) for sitagliptin. The most frequently reported adverse events in both semaglutide groups were gastrointestinal in nature: nausea was reported in 73 (18%) who received semaglutide 0·5 mg, 72 (18%) who received semaglutide 1·0 mg, and 30 (7%) who received placebo, and diarrhoea was reported in 54 (13%) who received semaglutide 0·5 mg, 53 (13%) who received semaglutide 1·0 mg, and 29 (7%) who received placebo. Seven (2%) patients in the semaglutide 0·5 mg group, two (<1%) in the semaglutide 1·0 mg group, and five (1%) in the sitagliptin group had blood-glucose confirmed hypoglycaemia. There were six fatal events (two in the semaglutide 0·5 mg group, one in the semaglutide 1·0 mg group, and three in the sitagliptin group); none were considered likely to be related to the trial drugs. INTERPRETATION: Once-weekly semaglutide was superior to sitagliptin at improving glycaemic control and reducing bodyweight in participants with type 2 diabetes on metformin, thiazolidinediones, or both, and had a similar safety profile to that of other GLP-1 receptor agonists. Semaglutide seems to be an effective add-on treatment option for this patient population. FUNDING: Novo Nordisk A/S.

来源:Lancet Diabetes Endocrinol,查看原文。版权归原作者所有。

引用

  1. Ahrén B, Masmiquel L, Kumar H, et al. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial. Lancet Diabetes Endocrinol. 2017. PMID: 28385659. doi:10.1016/S2213-8587(17)30092-X

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。